Review Article

Preeclampsia and Eclampsia Revisited

Authors: Sherri A. Longo, MD, Chi P. Dola, MD, Gabriella Pridjian, MD

Abstract

Hypertensive disorders during pregnancy, which account for approximately 15% of pregnancy-related deaths, represent the second-leading cause of morbidity and mortality in the United States. New classifications recommended by the National Institutes of Health's Working Group on High Blood Pressure in Pregnancy have decreased the confusion often associated with these disorders. The cause of preeclampsia-eclampsia still remains elusive, but continued research has provided hope with regard to screening, improved diagnosis, and management. Risk factors that have recently gained attention include inherited thrombophilias, inherited metabolic disorders, and lipid disorders. Treatment and management of the hypertensive disorders of pregnancy have not changed substantially in the past 50 years. Prevention of preeclampsia-eclampsia has been unsuccessful, and recurrence risks remain high. Careful diagnosis, classification, and further investigation of the causes of hypertensive disorders in pregnancy are needed to achieve optimal management of affected women and their fetuses.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Maguire DL. The treatment of puerperal eclampsia by caesarian section. South Med J 1909; 2: 1076–1079.
 
2. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1–S22.
 
3. Cunningham FG, Lindheimer MD. Hypertension in pregnancy. N Engl J Med 1992; 326: 927–931.
 
4. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001; 97: 533–538.
 
5. Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. ACOG technical bulletin: Hypertension in pregnancy—Number 219: January 1996 (replaces no. 91, February 1986). Int J Gynaecol Obstet 1996; 53: 175–183.
 
6. Garovic VD. Hypertension in pregnancy: Diagnosis and treatment. Mayo Clin Proc 2000; 75: 1071–1076.
 
7. Saftlas AF, Olson DR, Franks AL, et al. Epidemiology of preeclampsia and eclampsia in the United States, 1979–1986. Am J Obstet Gynecol 1990; 163: 460–465.
 
8. Lindheimer MD. Hypertension in pregnancy. Hypertension 1993; 22: 127–137.
 
9. Cerón-Mireles P, Harlow SD, Sánchez-Carrillo CI, et al. Risk factors for pre-eclampsia/eclampsia among working women in Mexico City. Paediatr Perinat Epidemiol 2001; 15: 40–46.
 
10. Burrows RF, Burrows EA. The feasibility of a control population for a randomized controlled trial of seizure prophylaxis in the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1995; 173: 929–935.
 
11. Cunningham FG, Gant NF, Leveno KJ, et al. Hypertensive disorders in pregnancy, in Williams Obstetrics. New York, McGraw-Hill Health Professions Division, 2001, ed 21, pp 567–618.
 
12. National High Blood Pressure Education Program. Working Group Report on High Blood Pressure in Pregnancy (NIH Publication No. 00-3029). Bethesda, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services, revised July 2000. Available at: http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_preg.pdf. Accessed June 24, 2003.
 
13. Pridjian G. Placental transfer, fetomaternal interaction: Placental physiology and its role as go between, in Avery GB, Fletcher MA, MacDonald MG (eds): Neonatology: Pathophysiology and Management of the Newborn. Philadelphia, Lippincott Williams & Wilkins, 1999, ed 5, pp 125–131.
 
14. Pirani BB, Campbell DM, MacGillivray I. Plasma volume in normal first pregnancy. J Obstet Gynaecol Br Commonw 1973; 80: 884–887.
 
15. Scott DE. Anemia during pregnancy. Obstet Gynecol Annu 1972; 1: 219–244.
 
16. Hunter S, Robson SC. Adaptation of the maternal heart in pregnancy. Br Heart J 1992; 68: 540–543.
 
17. Clapp JF III, Capeless E. Cardiovascular function before, during, and after the first and subsequent pregnancies. Am J Cardiol 1997; 80: 1469–1473.
 
18. Lang RM, Pridjian G, Feldman T, et al. Left ventricular mechanics in preeclampsia. Am Heart J 1991; 121: 1768–1775.
 
19. Robson SC, Hunter S, Boys RJ, et al. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 1989; 256: H1060–H1065.
 
20. Chapman AB, Abraham WT, Zamudio S, et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int 1998; 54: 2056–2063.
 
21. Gant NF, Chand S, Whalley PJ, et al. The nature of pressor responsiveness to angiotensin II in human pregnancy. Obstet Gynecol 1974; 43: 854–860.
 
22. Chesley LC, Talledo OE, Bohler CS, et al. Vascular reactivity to angiotensin II and norepinephrine in pregnant and nonpregnant women. Am J Obstet Gynecol 1965; 91: 837–841.
 
23. Lopez-Jaramillo P. Calcium, nitric oxide, and preeclampsia. Semin Perinatol 2000; 24: 33–36.
 
24. Nisell H, Hjemdahl P, Linde B, et al. Sympathoadrenal and cardiovascular reactivity in pregnancy-induced hypertension: Part II—Responses to tilting. Am J Obstet Gynecol 1985; 152: 554–560.
 
25. August P, Lindheimer MD. Chronic hypertension and pregnancy, in Lindheimer MD, Roberts JM, Cunningham FG (eds): Chesley's Hypertensive Disorders in Pregnancy. New York, McGraw-Hill Health Professions Division, 1999, ed 2, pp 615–616.
 
26. Cockburn J, Moar VA, Ounsted M, et al. Final report of study on hypertension during pregnancy: The effects of specific treatment on the growth and development of the children. Lancet 1982; 1: 647–649.
 
27. Redman CW. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet 1976; 2: 753–756.
 
28. Buttar HS. An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development. Mol Cell Biochem 1997; 176: 61–71.
 
29. Sibai BM, Mabie WC, Shamsa F, et al. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990; 162: 960–967.
 
30. Mabie WC, Pernoll ML, Biswas MK. Chronic hypertension in pregnancy. Obstet Gynecol 1986; 67: 197–205.
 
31. Rey E, Couturier A. The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol 1994; 171: 410–416.
 
32. Centers for Disease Control and Prevention. Maternal mortality: United States, 1982–1996. MMWR Morb Mortal Wkly Rep 1998; 47: 705–707.
 
33. U.S. Department of Health, Education, and Welfare. The Collaborative Perinatal Study of the National Institute of Neurological Diseases and Stroke: The Women and their Pregnancies(DHEW Publication No. (NIH) 73-379). Bethesda, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, 1972.
 
34. Li DK, Wi S. Changing paternity and the risk of preeclampsia/eclampsia in the subsequent pregnancy. Am J Epidemiol 2000; 151: 57–62.
 
35. Trupin LS, Simon LP, Eskenazi B. Change in paternity: A risk factor for preeclampsia in multiparas. Epidemiology 1996; 7: 240–244.
 
36. Barron WM. The syndrome of preeclampsia. Gastroenterol Clin North Am 1992; 21: 851–872.
 
37. Bozzo M, Carpani G, Leo L, et al. HELLP syndrome and factor V Leiden. Eur J Obstet Gynecol Reprod Biol 2001; 95: 55–58.
 
38. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9–13.
 
39. van Pampus MG, Dekker GA, Wolf H, et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180: 1146–1150.
 
40. Powers RW, Evans RW, Majors AK, et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998; 179: 1605–1611.
 
41. Alsulyman OM, Castro MA, Zuckerman E, et al. Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome. Obstet Gynecol 1996; 88: 644–646.
 
42. Shehata HA, Nelson-Piercy C, Khamashta MA. Management of pregnancy in antiphospholipid syndrome. Rheum Dis Clin North Am 2001; 27: 643–659.
 
43. Tyni T, Ekholm E, Pihko H. Pregnancy complications are frequent in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Am J Obstet Gynecol 1998; 178: 603–608.
 
44. Pridjian G, Puschett JB. Preeclampsia: Part 2—Experimental and genetic considerations. Obstet Gynecol Surv 2002; 57: 619–640.
 
45. Pridjian G, Puschett JB. Preeclampsia: Part 1—Clinical and pathophysiologic considerations. Obstet Gynecol Surv 2002; 57: 598–618.
 
46. Pridjian G, Ianosi MY, Williams J, et al. Volume expansion as a proximate cause of preeclampsia in a rat model, in Abstracts of the 13th World Congress of the International Society for the Study of Hypertension in Pregnancy, June 2–4, 2002, Toronto, ON, Canada.
 
47. Cross JC, Werb Z, Fisher SJ. Implantation and the placenta: Key pieces of the development puzzle. Science 1994; 266: 1508–1518.
 
48. Gallery ED, Lindheimer MD. Pathology and pathophysiology of preeclampsia: Alterations in volume homeostasis, in Lindheimer MD, Roberts JM, Cunningham FG (eds): Chesley's Hypertensive Disorders in Pregnancy. New York, McGraw-Hill Health Professions Division, 1999, ed 2, pp 327–347.
 
49. Knox TA, Olans LB. Liver disease in pregnancy. N Engl J Med 1996; 335: 569–576.
 
50. Morris RH, Vassalli P, Beller PK, et al. Immunofluorescent studies of renal biopsies in the diagnosis of toxemia of pregnancy. Obstet Gynecol 1964; 24: 32–46.
 
51. Parks DA, Granger DN. Xanthine oxidase: Biochemistry, distribution and physiology. Acta Physiol Scand Suppl 1986; 548: 87–99.
 
52. Hayashi TT. The effect of Benemid on uric acid excretion in normal pregnancy and in preeclampsia. Am J Obstet Gynecol 1957; 73: 17–22.
 
53. Katz M, Berlyne GM. Differential renal protein clearance in toxaemia of pregnancy. Nephron 1974; 13: 212–220.
 
54. Cunningham FG, Gant NF, Leveno KJ, et al. Hypertensive disorders in pregnancy, in Williams Obstetrics. New York, McGraw-Hill Health Professions Division, 2001, ed 21, pp 567–618.
 
55. Maynard JR, Dreyer BE, Stemerman MB, et al. Tissue-factor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts. Blood 1977; 50: 387–396.
 
56. Pritchard JA, Pritchard SA. Standardized treatment of 154 consecutive cases of eclampsia. Am J Obstet Gynecol 1975; 123: 543–552.
 
57. Lopez-Llera M. Complicated eclampsia: Fifteen years’ experience in a referral medical center. Am J Obstet Gynecol 1982; 142: 28–35.
 
58. Ferrazzani S, Caruso A, De Carolis S, et al. Proteinuria and outcome of 444 pregnancies complicated by hypertension. Am J Obstet Gynecol 1990; 162: 366–371.
 
59. Lindheimer MD, Davison JM. Renal biopsy during pregnancy: “To b … or not to b …?” Br J Obstet Gynaecol 1987; 94: 932–934.
 
60. Barron WM, Heckerling P, Hibbard JU, et al. Reducing unnecessary coagulation testing in hypertensive disorders of pregnancy. Obstet Gynecol 1999; 94: 364–370.
 
61. Witlin AG, Saade GR, Mattar F, et al. Risk factors for abruptio placentae and eclampsia: Analysis of 445 consecutively managed women with severe preeclampsia and eclampsia. Am J Obstet Gynecol 1999; 180: 1322–1329.
 
62. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: A severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982; 142: 159–167.
 
63. Crosby ET. Obstetrical anaesthesia for patients with the syndrome of haemolysis, elevated liver enzymes and low platelets. Can J Anaesth 1991; 38: 227–233.
 
64. Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993; 169: 1000–1006.
 
65. Odendaal HJ, Pattinson RC, Bam R, et al. Aggressive or expectant management for patients with severe preeclampsia between 28–34 weeks’ gestation: A randomized controlled trial. Obstet Gynecol 1990; 76: 1070–1075.
 
66. Sibai BM, Mercer BM, Schiff E, et al. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks’ gestation: A randomized controlled trial. Am J Obstet Gynecol 1994; 171: 818–822.
 
67. Spinnato JA. Sibai BM. Anderson GD. Fetal distress after hydralazine therapy for severe pregnancy-induced hypertension. South Med J 1986; 79: 559–562.
 
68. Clark SL, Cotton DB. Clinical indications for pulmonary artery catheterization in the patient with severe preeclampsia. Am J Obstet Gynecol 1988; 158: 453–458.
 
69. Sibai BM, Lindheimer M, Hauth J, et al. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension: National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 339: 667–671.
 
70. Dekker GA. Risk factors for preeclampsia. Clin Obstet Gynecol 1999; 42: 422–435.
 
71. Rey E, Couturier A. The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol 1994; 171: 410–416.
 
72. McCowan LM, Buist RG, North RA, et al. Perinatal morbidity in chronic hypertension. Br J Obstet Gynaecol 1996; 103: 123–129.
 
73. Hauth JC, Goldenberg RL, Parker CR Jr, et al. Low-dose aspirin therapy to prevent preeclampsia. Am J Obstet Gynecol 1993; 168: 1083–1093.
 
74. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343: 619–629.
 
75. Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women: The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1993; 329: 1213–1218.
 
76. Belizan JM, Villar J, Gonzalez L, et al. Calcium supplementation to prevent hypertensive disorders of pregnancy. N Engl J Med 1991; 325: 1399–1405.
 
77. Atallah AN, Hofmeyr GJ, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2000; 3: CD001059.
 
78. Ziaei S, Hantoshzadeh S, Rezasoltani P, et al. The effect of garlic tablet on plasma lipids and platelet aggregation in nulliparous pregnants at high risk of preeclampsia. Eur J Obstet Gynecol Reprod Biol 2001; 99: 201–206.
 
79. Laivuori H, Hovatta O, Viinikka L, et al. Dietary supplementation with primrose oil or fish oil does not change urinary excretion of prostacyclin and thromboxane metabolites in pre-eclamptic women. Prostaglandins Leukot Essent Fatty Acids 1993; 49: 691–694.
 
80. Ehrenberg A. Non-medical prevention of pre-eclampsia. Acta Obstet Gynecol Scand Suppl 1997; 164: 108–110.
 
81. Chappell LC, Seed PT, Briley AL, et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: A randomised trial. Lancet 1999; 354: 810–816.
 
82. Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: Subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986; 155: 1011–1016.
 
83. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: Recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991; 165: 1408–1412.
 
84. Sibai BM. Management and counseling of patients with preeclampsia remote from term. Clin Obstet Gynecol 1992; 35: 426–436.
 
85. Ihle BU, Long P, Oats J. Early onset pre-eclampsia: Recognition of underlying renal disease. Br Med J (Clin Res Ed) 1987; 294: 79–81.
 
86. Alsulyman OM, Castro MA, Zuckerman E, et al. Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome. Obstet Gynecol 1996; 88: 644–646.